Processa Pharmaceuticals ... (PCSA)
NASDAQ: PCSA
· Real-Time Price · USD
0.33
0.03 (9.78%)
At close: Jun 09, 2025, 3:59 PM
Processa Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | n/a | -2.73M | -3.38M | -3.01M | -2.73M | -2.4M | -2.08M | -2.61M | -4.02M | -13.01M | -6.02M | -5.16M | -3.23M | -3.18M | -2.99M | -3.16M | -2.1M |
Depreciation & Amortization | n/a | 301.00 | 203.00 | 139.00 | 139.00 | 140.00 | 82.00 | 20.18K | 19.8K | 197.12K | 197.12K | 197.12K | 197.12K | 197.12K | 195.7K | 198.83K | 199.32K |
Stock-Based Compensation | n/a | 155.05K | 154.19K | 152.63K | 167.64K | 256.82K | 142.89K | 319.12K | 341.5K | 2.78M | 3.21M | 2.01M | 828.9K | 1.15M | 1.08M | 865.32K | 308.3K |
Other Working Capital | n/a | 133.98K | -152.95K | -1.01M | 344.59K | 37.81K | 50.19K | 286.48K | 246.66K | 199.66K | -86.14K | 46.12 | 275.32K | -594.38K | 188.49K | -231.87K | -439.19K |
Other Non-Cash Items | n/a | 22.48K | 22.03K | -323.51K | 45.54K | 312.76K | 20.57K | 20.18K | 1.33M | 7.33M | 58.34K | 249.23K | 25.67K | 21.75K | 21.3K | 157.1K | 20.45K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | -291.78K | n/a | -20.18K | -19.8K | n/a | n/a | n/a | n/a | -181.75K | -122.44K | -137.17K | -89.25K |
Change in Working Capital | n/a | 303.15K | -394.33K | -509.57K | 488.34K | 3.13K | 157.47K | 208.79K | 235.82K | 216.15K | -423.18K | 378.13K | 372.51K | -730.45K | 255.59K | -121.01K | -582.86K |
Operating Cash Flow | n/a | -2.25M | -3.6M | -3.35M | -2.05M | -2.12M | -1.76M | -2.06M | -2.11M | -2.5M | -2.97M | -2.33M | -1.8M | -2.73M | -1.55M | -2.19M | -2.24M |
Capital Expenditures | n/a | n/a | -3.24K | n/a | n/a | n/a | -2.78K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | -3.24K | n/a | n/a | n/a | -2.78K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | n/a | -1.46K | -1.44K | -1.41K | -895 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | -312 | -3.66K | -2.01K | -9.92K | 52.75K | -52.75K | n/a | n/a | -53.6K | -35.25K | n/a | -300K | -36.42K | -27.98K | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 4.44M | -312 | n/a | n/a | -8.56K | -52.75K | n/a | n/a | n/a | n/a | -35.25K | n/a | n/a | -6.21K | -157.2K | -23.09K | n/a |
Financial Cash Flow | 4.44M | 547.58K | 926.2K | -3.41K | 6.26M | -30.61K | -52.75K | n/a | 6.35M | -53.6K | -35.25K | n/a | -300K | 131.36K | -185.18K | -23.09K | 9.88M |
Net Cash Flow | 1.71M | -1.7M | -2.68M | -3.35M | 4.21M | -2.15M | -1.82M | -2.06M | 4.24M | -2.55M | -3.01M | -2.33M | -2.1M | -2.6M | -1.74M | -2.22M | 7.63M |
Free Cash Flow | n/a | -2.25M | -3.61M | -3.35M | -2.05M | -2.12M | -1.76M | -2.06M | -2.11M | -2.5M | -2.97M | -2.33M | -1.8M | -2.73M | -1.55M | -2.19M | -2.24M |